Equities researchers at StockNews.com initiated coverage on shares of NeuroMetrix (NASDAQ:NURO – Get Free Report) in a research report issued on Sunday. The brokerage set a “sell” rating on the medical device company’s stock.
NeuroMetrix Stock Performance
Shares of NURO opened at $3.39 on Friday. The business has a 50-day moving average of $3.32 and a 200 day moving average of $4.56. NeuroMetrix has a fifty-two week low of $2.85 and a fifty-two week high of $15.04. The firm has a market cap of $3.63 million, a P/E ratio of -0.61 and a beta of 2.22.
Institutional Investors Weigh In On NeuroMetrix
Large investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its holdings in NeuroMetrix by 6.7% in the 1st quarter. Vanguard Group Inc. now owns 315,137 shares of the medical device company’s stock worth $1,311,000 after acquiring an additional 19,667 shares during the last quarter. Renaissance Technologies LLC grew its holdings in NeuroMetrix by 46.4% during the 2nd quarter. Renaissance Technologies LLC now owns 44,113 shares of the medical device company’s stock valued at $162,000 after buying an additional 13,985 shares in the last quarter. Citadel Advisors LLC grew its holdings in NeuroMetrix by 44.3% during the 3rd quarter. Citadel Advisors LLC now owns 34,699 shares of the medical device company’s stock valued at $97,000 after buying an additional 10,652 shares in the last quarter. Virtu Financial LLC purchased a new position in NeuroMetrix during the 1st quarter valued at about $78,000. Finally, Northern Trust Corp purchased a new position in NeuroMetrix during the 2nd quarter valued at about $41,000. Hedge funds and other institutional investors own 5.07% of the company’s stock.
NeuroMetrix Company Profile
NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, China, the Middle East, and Mexico. Its primary marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system, a platform for the performance of nerve conduction studies.
- Five stocks we like better than NeuroMetrix
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- 3 attractive stocks that insiders are buying
- What is a Secondary Public Offering? What Investors Need to Know
- Alpha and Omega Semiconductor ready to bounce, DOJ cloud lifts
- How Investors Can Find the Best Cheap Dividend Stocks
- Wendy’s vs Shake Shack: Out with the new, in with the old?
Receive News & Ratings for NeuroMetrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroMetrix and related companies with MarketBeat.com's FREE daily email newsletter.